Office for Technology Commercialization

Reversible, Non-Hormonal Male Contraceptive

Technology #z09075

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Male Birth ControlMale Birth Control
Gunda Georg, PhD
Medicinal Chemistry, College of Pharmacy
External Link (
Shameem Syeda
Research Assistant, Institute for Therapeutics Discovery and Development, College of Pharmacy
Gustavo Blanco, MD, PhD
Associate Professor, Department of Molecular and Integrative Physiology, University of Kansas
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

US Patent Pending 2014-0005132

Male Birth Control Reduces Sperm Motility

A reversible, non-hormonal male birth control method is possible by inhibiting the alpha-4 isoform of the sodium-potassium-transporting ATP-ases of the cells in the male gametes. The alpha-4 isoform is only present in sperm and by specifically inhibiting the alpha-4 isoform the pathway that is responsible for sperm motility becomes blocked and the sperm are unable to fertilize the egg in vitro. Reversibility is a major benefit of this contraception method because the agents are targeting sperm motility rather than trying to reduce the sperm count as in other hormonal methods.

MN-IP Try and Buy
  • Trial period up to 18 months. $5000/6 months.
  • Fee waived if MN operating company or if sponsoring $50,000+ in research.
  • Exclusive license for a $25,000 conversion payment.
  • No patent expenses.
  • 1.5% royalty after $1 million in product sales. 1.0% for MN companies.

** View the Term Sheet **
** Contact Kevin Anderson for specific details. **

Reversible Contraception Alternative to Vasectomy Procedures

Currently there are no other options on the market for male contraceptive beyond condoms and vasectomies, two methods that only account for 20% of contraception. Only 500,000 American men each year opt for the vasectomy procedure for their contraceptive method, an invasive procedure that is only 33% irreversible. New options for male birth control have been developed in the form of hormonal and non-hormonal agents. Our non-hormonal contraception method specifically targets sperm motility by blocking the pathway that leads to the reduction in the motility of the sperm and is reversible. The target specificity of the non-hormonal agents is expected to prevent systemic side effects that are often seen with hormonal methods. The male hormonal method is currently the closest to market but has shown depressed levels of good cholesterol (HDL-C), a side effect with potential long term impact on the cardiovascular system.


  • Reduction in sperm motility prevents fertilization of the egg
  • Vasectomy and condom alternative
  • Effective male contraception method with fewer systemic side effects
  • Reversible

Fulfillment Details Licensee will receive rights to practice the intellectual property (patent application) for the purposes of developing and manufacturing a commercial product.

Phase of Development Agent derivatives have been prepared for both in vitro and in vivo studies.